Latest Breaking News On - தாமஸ் ஹான்கே - Page 1 : comparemela.com
Evotec SE (via Public) / Evotec launches PRROTECT , a pre-competitive initiative to be better prepared for future pandemics
publicnow.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from publicnow.com Daily Mail and Mail on Sunday newspapers.
Evotec Launches PRROTECT , A Pre-Competitive Initiative to Be Better Prepared for Future Pandemics
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Evotec launches PRROTECT , a pre-competitive initiative to be better prepared for future pandemics
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
Search jobs 06-May-2021 Evotec launches beLAB1407 to accelerate translational research from the UK s academic life science ecosystem in collaboration with Bristol Myers Squibb
DGAP-News: Evotec SE / Key word(s): Miscellaneous
06.05.2021 / 07:30
beLAB1407 TRANSLATES ACADEMIC INNOVATION FROM LEADING ACADEMIC INSTITUTIONS IN THE UK
THE COLLABORATION LEVERAGES EVOTEC S UNIQUE MULTIMODALITY PLATFORM TO VALIDATE FIRST-IN-CLASS THERAPEUTIC CONCEPTS FROM THE UNIVERSITIES OF BIRMINGHAM, EDINBURGH, NOTTINGHAM, AND DUNDEE
BRISTOL MYERS SQUIBB JOINS beLAB1407 AS A BIOPHARMA COLLABORATOR
Hamburg, Germany, 06 May 2021:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that the Company, together with Bristol-Myers Squibb Company (NYSE: BMY), has launched beLAB1407, a new $ 20 m academic BRIDGE to identify and advance novel and breakthrough drug discovery opportunities across therapeutic areas from
Evotec invests into Oxford Cell Therapy Company OxVax
Search jobs Evotec invests into Oxford Cell Therapy Company OxVax
Evotec is co-leading investment into OxVax, a spinout from Oxford University, which is formed with the objective of producing first-in-class cancer vaccines.
Hamburg, Germany, 21 April 2021:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that the Company has invested into OxVax, a new immuno-oncology company based on research from Oxford University, which enables the development of the next generation of cancer vaccines with the potential to overcome the limitations of the current approaches.
OxVax is developing an innovative cancer vaccine platform based on a unique and proprietary population of dendritic cells capable of inducing a potent anti-tumour immune response. The company s technology allows the bulk manufacture of these cells from donor blood derived stem cells. By ex vivo lo